País: Canadá
Idioma: inglés
Fuente: Health Canada
MYCOPHENOLATE MOFETIL
ACCEL PHARMA INC
L04AA06
MYCOPHENOLIC ACID
250MG
CAPSULE
MYCOPHENOLATE MOFETIL 250MG
ORAL
100
Prescription
IMMUNOSUPPRESSIVE AGENTS
Active ingredient group (AIG) number: 0128158001; AHFS:
CANCELLED PRE MARKET
2017-05-19
PRODUCT MONOGRAPH Pr ACCEL-MYCOPHENOLATE MOFETIL CAPSULES Mycophenolate mofetil Capsules – 250 mg Pharmaceutical standard house Immunosuppressive Agent Accel Pharma Inc. 99 Place Frontenac Pointe-Claire, QC, H9R 4Z7 Canada Date of Preparation: January 28, 2013 Submission Control No: 161660 _ _ _Accel-Mycophenolate Mofetil Capsules _ _Page 2 of 58_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................7 DRUG INTERACTIONS ..................................................................................................15 DOSAGE AND ADMINISTRATION ..............................................................................18 OVERDOSAGE ................................................................................................................20 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 STORAGE AND STABILITY ..........................................................................................26 SPECIAL HANDLING INSTRUCTIONS .......................................................................27 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................27 PART II: SCIENTIFIC INFORMATION ...............................................................................28 PHARMACEUTICAL INFORMATION ..........................................................................28 CLINICAL TRIALS ............................... Leer el documento completo